Source: Virtual Congress 2021 – Pearls in immunology, outcome studies and clinical trials in asthma, alpha-1 antitrypsin deficiency and COPD



Rating:

Share or cite this content

Citations should be made in the following way:
I. Barjaktarevic (Los Angeles, United States of America), A. Manichaikul (Charlottsville, United States of America), D. Markovic (Los Angeles, United States of America), R. Hixson (Los Angeles, United States of America), C. Cooper (Los Angeles, United States of America), R. Buhr (Los Angeles, United States of America), R. Barr (New York, United States of America), J. Curtis (Ann Arbor, United States of America), M. Drummond (Chapell Hill, United States of America), S. Fortis (Iowa City, United States of America), G. Hawkins (Winston-Salem, United States of America), M. Han (Ann Arbor, United States of America), E. Hoffman (Iowa City, United States of America), V. Kim (Philadelphia, United States of America), X. Li (Tucson, United States of America), F. Martinez (Ithaca, United States of America), R. Paine Iii (Salt Lake City, United States of America), C. Pirozzi (Salt Lake City, United States of America), D. Tashkin (Los Angeles, United States of America), J. Wells (Birmingham, United States of America), P. Woodruff (San Francisco, United States of America), D. Meyers (Tucson, United States of America), E. Bleecker (Tucson, United States of America), V. Ortega (Winston-Salem, United States of America). Clinical consequences and longitudinal outcomes in PiMZ heterozygous a1-antitrypsin deficiency smokers from SPIROMICS. 2834

Member's Comments

No comment yet.

Related content which might interest you: Clinical considerations in individuals with a1-antitrypsin PI*SZ genotype Source: Eur Respir J, 55 (6) 1902410; 10.1183/13993003.02410-2019 Year: 2020 Clinical, functional, radiologic and quality of life characteristics in PI*SZ Alpha 1-Antitrypsin Deficiency (AATD) compared to PI*ZZ, PI*MZ and COPD without AATD: a retrospective cohort study. Source: Virtual Congress 2021 – Biomarkers to phenotype COPD: prediction of exacerbations Year: 2021 a1-antitrypsin PI*SZ genotype: a SERPINA1 deficiency haplotype with uncertain clinical and therapeutic implications Source: Eur Respir J, 55 (6) 2000713; 10.1183/13993003.00713-2020 Year: 2020 Risk of cancer in individuals with severe alpha-1-antitrypsin deficiency (PiZZ) compared with the Swedish general population Source: Virtual Congress 2020 – Asthma and COPD: How genetic and environment influences its developement? Year: 2020 Clinical phenotype of individuals with common COPD investigated during the targeted detection programme for alpha1-antitrypsin deficiency in Italy Source: Annual Congress 2007 - Clinical aspects in COPD Year: 2007 Prevalence of alpha-1-antitrypsin deficiency (A1AD) in patients with COPD. Source: Virtual Congress 2021 – COPD burden, epidemiology and management Year: 2021 Health status changes in patients with alpha-1-antitrypsin deficiency Source: Eur Respir J 2002; 20: Suppl. 38, 249s Year: 2002 Clinical phenotypes of Italian and Spanish patients with a1-antitrypsin deficiency Source: Eur Respir J 2013; 42: 54-64 Year: 2013 Mortality in individuals with severe alpha-1-antitrypsin deficiency (PiZZ) Source: Eur Respir J 2006; 28: Suppl. 50, 144s Year: 2006 Survival in individuals with severe alpha 1-antitrypsin deficiency (PiZZ) in comparison to a general population with known smoking habits Source: Eur Respir J, 50 (3) 1700198; 10.1183/13993003.00198-2017 Year: 2017 Exacerbations and duration of smoking abstinence are associated with the annual decline in lung function in individuals with PiZZ alpha-1-antitrypsin deficiency Source: International Congress 2017 – Current challenges in COPD evaluation Year: 2017 Differences of disease phenotypes in individuals with alpha-1-antitrypsin deficiency with genotypes PiZZ and PiSZ - Analysis from the German registry Source: International Congress 2016 – Phenotyping and monitoring airway diseases Year: 2016 Health status changes in alpha-1-antitrypsin deficiency (PiZ phenotype) over 3 years Source: Annual Congress 2003 - Alpha-1 antitrypsin deficiency and COPD Year: 2003 Effect of danazol on acute phase reactants in patients with PiM, PiMZ and PiZ phenotypes for alpha-1-antitrypsin deficiency Source: Eur Respir J 2001; 18: Suppl. 33, 249s Year: 2001 Plasma levels of soluble CD14 in asymptomatic PiZZ and PiSZ subjects. Follow-up of the Swedish neonatal screening cohort Source: Annual Congress 2007 - Unravelling molecular mysteries of COPD Year: 2007 Prevalence and phenotype of subjects carrying rare variants in Argentina for alpha1-antitrypsin deficiency Source: International Congress 2017 – Current molecular and genetic understanding of lung diseases Year: 2017 Clinical impact of vitamin D deficiency on Tunisian asthmatics Source: International Congress 2017 – Biomarker-based asthma control Year: 2017 Prevalence of alpha1-antitrypsin deficiency and its influence on lung function decline in patients with severe asthma Source: Virtual Congress 2020 – Advances in asthma treatment Year: 2020 Differences in the disease phenotype and comorbidities between patients with COPD and alpha-1-antitrypsin deficiency - An analysis of the COSYCONET cohort Source: International Congress 2016 – Prevalence, prognosis, and risk factors of COPD Year: 2016 Study of pulmonary function in children with homozygous beta thalassemia Source: Eur Respir J 2002; 20: Suppl. 38, 140s Year: 2002